Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors

Author(s): Fatih M. Uckun, Alexei Vassilev, Ilker Dibirdik, Heather Tibbles

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 7 , Issue 6 , 2007

Become EABM
Become Reviewer


Inhibitors of Janus Kinase 3 (JAK3) show potential as a new class of apoptosis-inducing anti-cancer drugs. In addition, JAK3 inhibitors may also be useful as immunosuppressive agents. Rationally designed selective inhibitors of JAK3 such as JANEX-1, that do not inhibit other Janus kinases have recently undergone extensive preclinical testing that revealed a favorable pharmacodynamic profile. Here we discuss the clinical potential of targeting JAK3-linked signal transduction pathways with small molecule inhibitors such as JANEX-1.

Keywords: Rational Drug Design, Tyrosine Kinases, Inhibitors, JAK3

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [612 - 623]
Pages: 12
DOI: 10.2174/187152007784111304
Price: $65

Article Metrics

PDF: 8